Metal Ions Guided Self-assembly of Therapeutic Proteins for Controllable Release: From Random to Ordered Aggregation
Purchase on Springer.com
$39.95 / €34.95 / £29.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
To make a comparative study on sustained delivery performance of rhIFN with random amorphous and spherical crystal-like ordered self-assemblies.
The rhIFN self-assemblies were identified in batch crystallization mode. Physico-chemical characteristics were compared, including morphology, XRD, FTIR, CD, biological potency, the dissolution behaviors in vitro and plasma pharmacokinetics in vivo. Moreover, molecular simulation was performed to better understand their binding site and mode.
Here, we suggest that random amorphous and spherical ordered self-assemblies allow for long action without new molecular entities generation or carriers employed. By manipulating supersaturation, the ordered aggregates were self-organized at high concentration of Zn(II) (>100 mM) in pH 5.5–6.0, which was the first time that spherical semi-crystals of rhIFN can act as a depot source for the sustained delivery of biologically active proteins. The secondary structure and biological potency of rhIFN were unchanged after aggregation. Compared with that of the native rhIFN, both self-assemblies exhibited slower absorption and extended elimination profiles after s.c. administration, which were characterized as 4.75 ± 0.82 h and 10.58 ± 1.86 h of terminal half-life for random amorphous and spherical ordered self-assemblies, respectively.
The work described here demonstrates the possibility of self-assemblies of biomacromolecules for controllable release application of therapeutic proteins.
- Carter PJ. Introduction to current and future protein therapeutics: a protein engineering perspective. Exp Cell Res. 2011;317(9):1261–9. CrossRef
- Szlachcic A, Zakrzewska M, Otlewski J. Longer action means better drug: tuning up protein therapeutics. Biotechnol Adv. 2011;29(4):436–41. CrossRef
- Fu K, Klibanov AM, Langer R. Protein stability in controlled-release systems. Nat Biotechnol. 2000;18(1):24–5. CrossRef
- Kozlowski A, Charles SA, Harris JM. Development of Pegylated interferons for the treatment of chronic hepatitis C. BioDrugs. 2001;15(7):419–29. CrossRef
- Dusheiko G. Side effects of alpha interferon in chronic hepatitis C. Hepatology. 1997;26(3 Suppl 1):112S–21. CrossRef
- Putney SD, Burke PA. Improving protein therapeutics with sustained-release formulations. Nat Biotechnol. 1998;16(2):153–7. CrossRef
- Zhang L, Schwendeman SP. Injectable biodegradable polymer depots for minimally invasive delivery of peptides and proteins. Adv Exp Med Biol. 2009;611:611–3. CrossRef
- Sinha VR, Trehan A. Biodegradable microspheres for protein delivery. J Control Release. 2003;90(3):261–80. CrossRef
- Weiner AL. Liposomes for protein delivery: selecting manufacture and development processes. ImmunoMethods. 1994;4(3):201–9. CrossRef
- Nelson DM, Ma Z, Leeson CE, Wagner WR. Extended and sequential delivery of protein from injectable thermoresponsive hydrogels. J Biomed Mater Res A. 2012;100(3):776–85.
- Bailon P, Won CY. PEG-modified biopharmaceuticals. Expert Opin Drug Deliv. 2009;6(1):1–16. CrossRef
- Wang W, Nema S, Teagarden D. Protein aggregation–pathways and influencing factors. Int J Pharm. 2010;390(2):89–99. CrossRef
- Dobson CM. Principles of protein folding, misfolding and aggregation. Semin Cell Dev Biol. 2004;15(1):3–16. CrossRef
- Philo JS, Arakawa T. Mechanisms of protein aggregation. Curr Pharm Biotechnol. 2009;10(4):348–51. CrossRef
- Dunn MF. Zinc-ligand interactions modulate assembly and stability of the insulin hexamer – a review. Biometals. 2005;18(4):295–303. CrossRef
- Ding F, Dokholyan NV. Dynamical roles of metal ions and the disulfide bond in Cu, Zn superoxide dismutase folding and aggregation. Proc Natl Acad Sci U S A. 2008;105(50):19696–701. CrossRef
- Mattiasson B, Kumar A, Ivanov AE, Galaev IY. Metal-chelate affinity precipitation of proteins using responsive polymers. Nat Protoc. 2007;2(1):213–20. CrossRef
- Ochi T, Bolanos-Garcia VM, Stojanoff V, Moreno A. Perspectives on protein crystallisation. Prog Biophys Mol Biol. 2009;101(1–3):56–63. CrossRef
- Gietz U, Arvinte T, Häner M, Aebi U, Merkle HP. Formulation of sustained release aqueous Zn-hirudin suspensions. Eur J Pharm Sci. 2000;11(1):33–41. CrossRef
- Govardhan C, Khalaf N, Jung CW, Simeone B, Higbie A, Qu S, Chemmalil L, Pechenov S, Basu SK, Margolin AL. Novel long-acting crystal formulation of human growth hormone. Pharm Res. 2005;22(9):1461–70. CrossRef
- Jen A, Merkle HP. Diamonds in the rough: protein crystals from a formulation perspective. Pharm Res. 2001;18(11):1483–8. CrossRef
- Haris PI, Chapman D. Analysis of polypeptide and protein structures using Fourier transform infrared spectroscopy. Methods Mol Biol. 1994;22:183–202.
- Venyaminov YS, Yang JT. Determination of protein secondary structure. In: Fasman GD, editor. Ircular dichroism and the conforma tional analysis of biomolecules. New York: Plenum; 1996. p. 69–107.
- Yun J, Choi H. Micellar colorimetric determination of iron, cobalt, nickel and copper using 1-nitroso-2-naphthol. Talanta. 2000;52(5):893–902. CrossRef
- Hallas-Moller K, Petersen K, Schlichtkrull J. Crystalline and amorphous insulin-zinc compounds with prolonged action. Science. 1952;116(3015):394–8. CrossRef
- Basu SK, Govardhan CP, Jung CW, Margolin AL. Protein crystals for the delivery of biopharmaceuticals. Expert Opin Biol Ther. 2004;4(3):301–17. CrossRef
- Gránásy L, Pusztai T, Börzsönyi T, Warren JA, Douglas JF. A general mechanism of polycrystalline growth. Nat Mater. 2004;3(9):645–50. CrossRef
- Bassett DC. Polymer spherulites: a modern assessment. J Macromol Sci Phys. 2003;42(2):227–56. CrossRef
- Rogers SS, Krebs MR, Bromley EH, van der Linden E, Donald AM. Optical microscopy of growing insulin amyloid spherulites on surfaces in vitro. Biophys J. 2006;90(3):1043–54. CrossRef
- Wiencek JM. New strategies for protein crystal growth. Annu Rev Biomed Eng. 1999;1:505–34. CrossRef
- Chayen NE, Saridakis E. Protein crystallization: from purified protein to diffraction-quality crystal. Nat Methods. 2008;5:147–53. CrossRef
- Carter WA. Interferon: evidence for subunit structure. Proc Natl Acad Sci USA. 1970;67(2):620–8. CrossRef
- Frokjaer S, Otzen DE. Protein drug stability: a formulation challenge. Nat Rev Drug Discov. 2005;4:298–306. CrossRef
- Radhakrishnan R, Walter LJ, Hruza A, Reichert P, Trotta PP, Nagabhushan TL, Walter MR. Zinc mediated dimer of human interferon-alpha 2b revealed by X-ray crystallography. Structure. 1996;4(12):1453–63. CrossRef
- Favier A. Is zinc a cellular mediator in the regulation of apoptosis? metal ions in biology and medicine. In: Colley P, Bratter P, de Bratter VN, Khassanova L, Etienne JC, editors. Metal ions in biology and medicine volume 5. Paris: John Libbey Eurotex; 1998. p. 164–8.
- Walsh CT, Sandstead HH, Prasad AS, Newberne PM, Fraker PJ. Zinc: health effects and research priorities for the 1990s. Environ Health Perspect. 1994;102 Suppl 2:5–46. CrossRef
- Amidon GL, Lennernäs H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 1995;12(3):413–20. CrossRef
- Emami J. In vitro - in vivo correlation: from theory to applications. J Pharm Pharm Sci. 2006;9(2):169–89.
- Metal Ions Guided Self-assembly of Therapeutic Proteins for Controllable Release: From Random to Ordered Aggregation
Volume 30, Issue 1 , pp 269-279
- Cover Date
- Print ISSN
- Online ISSN
- Springer US
- Additional Links
- controllable release
- protein delivery
- spherical crystal
- Industry Sectors
- Author Affiliations
- 1. Department of Pharmaceutics, School of Pharmaceutical Science, Shenyang Pharmaceutical University, No. 103, Wenhua Road, Shenyang, 110016, China
- 2. Liaoning Yilian Institute of Materia Medica, No. 18, Sanhao Street, Shenyang, 110004, China
- 3. Liaoning Satellite Biotechnology Products Research Institute, No. 51-3, Dongzhan Street, Shenyang, 110044, China